Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Palisade Bio (NASDAQ: PALI), a clinical-stage biopharmaceutical company focused on developing therapeutics for autoimmune, inflammatory, and fibrotic diseases, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The company has issued stock options to a new employee as part of its 2021 Inducement Plan.
The grant consists of options to purchase 2,600 shares of common stock, issued on January 3, 2025, with an exercise price matching the closing price on the grant date. The options will vest quarterly over a three-year period, subject to continued employment with the company.
Palisade Bio (NASDAQ: PALI), una società biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie per malattie autoimmuni, infiammatorie e fibrotiche, ha annunciato un'offerta di incentivazione ai sensi della Regola 5635(c)(4) di Nasdaq. L'azienda ha emesso opzioni su azioni a un nuovo dipendente come parte del suo Piano di Incentivazione 2021.
L'offerta consiste in opzioni per acquistare 2.600 azioni ordinarie, rilasciate il 3 gennaio 2025, con un prezzo d'esercizio pari al prezzo di chiusura alla data dell'offerta. Le opzioni matureranno trimestralmente per un periodo di tre anni, soggetto a un impiego continuativo con l'azienda.
Palisade Bio (NASDAQ: PALI), una compañía biofarmacéutica en etapa clínica enfocada en el desarrollo de terapias para enfermedades autoinmunitarias, inflamatorias y fibrosas, ha anunciado una concesión de incentivos bajo la Regla de Cotización 5635(c)(4) de Nasdaq. La compañía ha emitido opciones sobre acciones a un nuevo empleado como parte de su Plan de Incentivos 2021.
La concesión consiste en opciones para comprar 2,600 acciones ordinarias, emitidas el 3 de enero de 2025, con un precio de ejercicio equivalente al precio de cierre en la fecha de la concesión. Las opciones se consolidarán trimestralmente durante un período de tres años, sujeto a la continuación del empleo con la compañía.
팔리세이드 바이오 (NASDAQ: PALI)는 자가 면역, 염증 및 섬유성 질환을 위한 치료제를 개발하는 임상 단계의 바이오 제약 회사로, Nasdaq 상장 규정 5635(c)(4)에 따라 유인 보조금을 발표했습니다. 이 회사는 2021년 유인 계획의 일환으로 새로운 직원에게 주식 옵션을 제공했습니다.
이번 보조금은 2,600주의 일반 주식을 구매할 수 있는 옵션으로 구성되며, 2025년 1월 3일에 발행되며, 행사 가격은 보조금 날의 종가와 동일합니다. 옵션은 회사와의 계속적인 고용 조건에 따라 3년 동안 분기마다 귀속됩니다.
Palisade Bio (NASDAQ: PALI), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies pour les maladies auto-immunes, inflammatoires et fibrosantes, a annoncé une attribution d'incitation conformément à la Règle de cotation 5635(c)(4) de Nasdaq. La société a émis des options sur actions à un nouvel employé dans le cadre de son Plan d'incitation 2021.
L'attribution consiste en des options d'achat de 2 600 actions ordinaires, émises le 3 janvier 2025, avec un prix d'exercice égal au prix de clôture à la date d'attribution. Les options seront acquises trimestriellement sur une période de trois ans, sous réserve de la poursuite de l'emploi au sein de l'entreprise.
Palisade Bio (NASDAQ: PALI), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von Therapeutika für Autoimmun-, Entzündungs- und fibrotische Erkrankungen konzentriert, hat unter der Nasdaq-Notierungsregel 5635(c)(4) einen Anreizzuschuss angekündigt. Das Unternehmen hat einem neuen Mitarbeiter im Rahmen seines Anreizplans 2021 Aktienoptionen gewährt.
Der Zuschuss besteht aus Optionen zum Kauf von 2.600 Aktien des Stammkapitals, die am 3. Januar 2025 ausgegeben werden, mit einem Ausübungspreis, der dem Schlusskurs am Zuschussdatum entspricht. Die Optionen werden vierteljährlich über einen Drei-Jahres-Zeitraum vesten, vorausgesetzt, dass das Arbeitsverhältnis mit dem Unternehmen fortgesetzt wird.
- None.
- None.
Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it had made an equity grant to a new employee under its 2021 Inducement Plan, as amended.
The Company approved the issuance of an option to purchase 2,600 shares of the Company’s common stock to a new employee, as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The option was issued on January 3, 2025, and has an exercise price equivalent to the closing price of the Company’s common stock on the date of grant. The option vests in equal proportions on a quarterly basis over three years with vesting being contingent on continuing to provide services to the Company through each vesting date.
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
FAQ
How many shares were included in PALI's January 2025 inducement grant?
What is the vesting schedule for PALI's January 2025 inducement grant?
When was PALI's latest inducement grant issued?
What is the exercise price for PALI's January 2025 stock options grant?
